NCT05061680

Brief Summary

ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla. The investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Apr 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Apr 2021Dec 2026

Study Start

First participant enrolled

April 5, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 20, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 29, 2021

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

March 1, 2023

Status Verified

February 1, 2023

Enrollment Period

4.7 years

First QC Date

September 20, 2021

Last Update Submit

February 28, 2023

Conditions

Outcome Measures

Primary Outcomes (3)

  • Rate of bleeding

    need for additional intervention or need for blood transfusion and hemoglobin drop more than 2 gm/dL

    30 days

  • Rate of pancreatitis

    Plasma amylase rises \>3 times the upper limit and newly developed stomach ace more than 24h

    30 days

  • Rate of cholangitis

    Fever \>38

    30 days

Study Arms (3)

short sphincterotomy +Short duration papillary large balloon dilation

ACTIVE COMPARATOR

Patients with short sphincterotomy

Device: endoscopic short duration papillary large balloon dilation

full sphincterotomy + short duration papillary balloon dilation

ACTIVE COMPARATOR

Patients with full lenght sphincterotomy

Device: endoscopic short duration papillary large balloon dilation

previous sphincterotomy + short duration papillary balloon dilation

ACTIVE COMPARATOR

Patients with previous sphincterotomy

Device: endoscopic short duration papillary large balloon dilation

Interventions

During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.

full sphincterotomy + short duration papillary balloon dilationprevious sphincterotomy + short duration papillary balloon dilationshort sphincterotomy +Short duration papillary large balloon dilation

Eligibility Criteria

Age18 Years - 95 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years
  • Common bile duct stone \>10mm diameter

You may not qualify if:

  • Altered anatomy after surgery (B II, Roux-en-Y reconstruction)
  • Common bile duct cysts
  • Acute pancreatitis
  • Distal common bile duct stricture or tumor
  • Coagulation disorders
  • Ongoing coagulation medication
  • Pregnancy
  • Inability to give an informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Helsinki University Hospital

Helsinki, Finland

RECRUITING

Turku University Hospital

Turku, Finland

RECRUITING

MeSH Terms

Conditions

PancreatitisHemorrhageCholangitis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsBile Duct DiseasesBiliary Tract Diseases

Study Officials

  • Mia Rainio, Md, PhD

    Helsinki University Central Hospital

    STUDY DIRECTOR

Central Study Contacts

Mia Rainio, MD, PhD

CONTACT

Leena Kylänpää, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 20, 2021

First Posted

September 29, 2021

Study Start

April 5, 2021

Primary Completion

December 31, 2025

Study Completion (Estimated)

December 31, 2026

Last Updated

March 1, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations